• Lexaria just announced ground-breaking findings from its recently-concluded Sildenafil animal study
• The success of this study sets the stage for various other studies on the use of the company’s patented DehydraTECH technology
• The company is set to commence dosing its most extensive hypertension study in April 2022, with results expected in Q3 2022
• Its successful completion could greatly enhance Lexaria’s leadership position in the global drug delivery market

Lexaria Bioscience (NASDAQ: LEXX) kicked off the 2022 calendar year by receiving independent review board approval for its upcoming DehydraTECH(TM)-CBD human hypertension study, HYPER-H21-4.  Additionally, in what marks another critical milestone, the company also reported ground-breaking findings from its sildenafil animal study. Chris Bunka, the Lexaria’s Chief Executive Officer (“CEO”), at the beginning of the year, noted the company’s commitment to achieving even more milestones with its patented DehydraTECH technology for a variety of conditions, including, but not limited to hypertension and heart disease. The success of this sildenafil study lives up to that resolve and sets the stage for more successful studies to come. “Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for investigation of heart disease and hypertension; and separately, for oral nicotine delivery as an alternative to smoking,” he noted (https://ibn.fm/hoS2E). He also added that in 2022 the company would explore the technology for the potential treatment of hormone replacement, rheumatoid disease, dementia, diabetes, and erectile dysfunction. The recent sildenafil study explored DehydraTECH’s processing of the phosphodiesterase inhibitor (“PDE5 inhibitor”), sildenafil, for the potential application in erectile dysfunction management. It revealed that DehydraTECH delivered 74% more sildenafil into the bloodstream on average compared to the concentration-matched, generic control formulation (https://ibn.fm/q2oCk). The success of this study could be beneficial to key brands such as Viagra or its generic pharmaceutical competitors. It also presents an opportunity for Lexaria to create even more value for its shareholders. The company plans to kick off what it refers to as the most extensive hypertension study in April of this year. Its execution and subsequent completion will allow Lexaria to stamp its position as a global drug delivery market leader. The estimated current global market for drugs used to treat various heart diseases is $96.1 billion and expected to be $107.8 billion in 2025. (https://ibn.fm/GsXgi). “If this study is successful, we feel strongly that it will be highly supportive of our IND filing plan, and we will have a clear path toward designing of Phase 1 and even potentially Phase II FDA-registered clinical studies thereunder,” noted Mr. Bunka. “Assuming there are no major delays either in study execution or evaluation, we expect full results from this study sometime in Q3, 2022,” he added (https://ibn.fm/UzsHq). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Studies suggest that psychedelics such as psilocybin and MDMA offer health benefits when used to treat patients with depression and PTSD
• These results have encouraged scientists, psychotherapists, and entrepreneurs, who say that FDA approvals may be on the horizon
• Mydecine is playing a vital role in pushing the knowledge of the benefits of psychedelic compounds by undertaking clinical research in partnership with academics
• In a recent interview, company CEO Josh Bartch emphasized the need for consistent messaging to push the adoption of psychedelics among the medical community, and help assuage concerns of patients who may be wary of psychedelic treatments

Fueled by the extremes of the counterculture witnessed in the ‘60s and ‘70s, psychedelics acquired a soiled reputation that drove stereotypical connotations, which are only wearing off years later thanks to efforts by researchers. Results from one study published in the New England Journal of Medicine, for example, showed the benefits of using psilocybin as a treatment for depression (https://ibn.fm/LfyUe). Another clinical trial published in the Nature Medicine journal established that MDMA (commonly known as Ecstasy and Molly) combined with counseling brought noticeable relief to patients with severe post-traumatic stress disorder (“PTSD”) (https://ibn.fm/rEBcb). As a result, a 2021 New York Times article observed that the scientific and psychotherapeutic communities had been enthused, further noting that “[scientists, psychotherapists, and entrepreneurs in the field of psychedelic medicine] say it is only a matter of time before the Food and Drug Administration grants approval for psychoactive compounds to be used therapeutically – for MDMA as soon as 2023, followed by psilocybin a year or two later” (https://ibn.fm/HujeN). These speculations are part of a rising tide of positivity that has seen the once heavily stereotyped and criticized class of drugs gaining widespread attention; in the United States, this is markedly bipartisan. At the center of this veritable renaissance, working alongside researchers, are organizations like Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), a biotechnology company aiming to transform the treatment of mental health and addiction disorders. Mydecine is playing a crucial role in advancing the knowledge of the benefits of psychedelics by developing innovative first and second-generation novel compounds for the treatment of mental health and addiction and sequentially collaborating with academics to undertake vital clinical research on them (https://ibn.fm/k8G8G). So far, Mydecine has partnered with Johns Hopkins University to launch a seamless phase 2/3 clinical trial utilizing psilocybin for smoking cessation. Led by Principal Investigator Dr. Matthew Johnson, Ph.D., Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University, the trial will evaluate the safety and efficacy of psilocybin-assisted psychotherapy using Mydecine’s lead drug candidate, MYCO-001, to treat tobacco addiction. Earlier this month, Mydecine submitted a pre-investigational new drug briefing package to the FDA for the trial (https://ibn.fm/OjsfH). The company also intends to supply MYCO-001 in a planned multi-site smoking cessation trial led by Dr. Johnson and funded via a grant from the National Institute on Drug Abuse (“NIDA”) and is planning a separate Phase 2A trial focusing on PTSD in veterans. To this end, Mydecine recently announced Combat Stress, a leading UK-based charity aiding veterans’ mental health, as one of multiple sites for their upcoming clinical trials. Additionally, Mydecine has partnered with Calgary-based Newly Institute Inc. to co-develop protocols and therapy manuals for different indications under their Special Access Support and Supply Program (“SASSP”) with the aim of expanding responsible, early-stage psychedelic-assisted therapy to patients (https://ibn.fm/bnmdH). And in a recent interview with Shadd Dales of The Dales Report, Mydecine CEO Josh Bartch stated that the company is looking to announce other similar partnerships in the coming weeks and months, specifically targeting large physician, therapy, and hospital networks (https://ibn.fm/ek2Yq). Bartch also emphasized the need to assuage those who are still wary of psychedelics, noting that for the majority of the population to trust psychedelics, the general medical community has to have adopted this class of drugs as well as integrated it into the regular medical conversation. This, according to Bartch, will require education as well as the portrayal and communication of data “in the right way to that mental health medical community.” And though it may take a long time to accomplish, “it’s definitely going to happen, and it’s possible through consistent messaging throughout the industry,” Bartch concluded. Valued at $3.21 billion in 2021, the psychedelic drug market is expected to reach $6.33 billion by 2026 (a 14.5% CAGR), buoyed by increased adoption of the drugs due to a large unmet need in the mental health segment (https://ibn.fm/y8KR0). For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• Company ranked as one of 50 most innovative New York-Based energy-management companies and startups
• Companies were selected based on exceptional performance in innovation, growth, management or societal impact
• StorEn also cited as partner with organization investigate battery storage options and increase the lifetime of redox flow batteries

StorEn Technologies, a developer of evolutionary vanadium flow batteries with a disruptive patent-pending, all-vanadium flow battery technology, was recently listed as one of the 50 Most Innovative New York Based Energy Management Companies & Startups by Futurology Inc. (https://ibn.fm/4VXZR). In addition, the company also garnered some attention from the Graphene Council, which called out the company in an article touting a surprise ingredient discovered in the search for improved electricity grid capacity (https://ibn.fm/iJ2wA). “This article showcases our top picks for the best New York-based Energy Management companies,” reported Futurology when releasing its 50 Most Innovative List. “These startups and companies are taking a variety of approaches to innovating the energy management industry, but are all exceptional companies well worth a follow.” Futurology noted that it had tried to select companies across the size spectrum from cutting-edge startups to established brands. The companies were selected based on exceptional performance in innovation, growth, management or societal impact, noted the article, which called out StorEn specifically for its efforts to bring proprietary real innovation to vanadium flow batteries. In its article titled “Schulich Researchers Discover Surprise Ingredient for Improved Electricity Grid Capacity,” the Graphene Council noted partners that were helping the organization in its quest to investigate battery storage options and increase the lifetime of redox flow batteries. “Not only are the researchers excited about the possibilities, but partners have also come forward,” the article noted. “The University of Waterloo and Kitchener-based Evercloak Inc. are working on the technology for coating the membrance with the graphene, while Roberts says his team will test the technology using a small five-kilowatt commercial redox flow battery in a research microgrid that is being built on-campus. The battery is being supplied by U.S. company, StorEn Technologies Inc.” The article stated that redox flow batteries, which store electrical energy in liquids that are pumped through the battery, are being developed for energy storage on electricity grids for things like managing intermittent renewable-energy generation. The article quoted Dr. Edward (Ted) Roberts, PhD, who has been investigating battery storage options, with a focus on increasing the lifetime of the batteries. “For electricity grid storage, batteries are flexible and can be implemented anywhere, but they are expensive,” says Roberts. “Key metrics for batteries are the round-trip efficiency, power density, energy density and lifetime. “Other battery technologies such as lithium-ion don’t have the flexibility of RFBs to increase the amount of energy stored, as more batteries are needed to do that,” Roberts continued. “RFBs offer design flexibility, have a longer lifetime and a lower cost per kilowatt-hour delivered over their lifetime.” StorEn has developed evolutionary vanadium flow batteries. Incubated at the Clean Energy Business Incubator Program (“CEBIP”) within Stony Brook University in New York, the company is building upon the strengths of vanadium flow batteries to revolutionize the world of residential and industrial energy storage. In part, StorEn’s technology has enhanced the electrical efficiency of the stack and energy density of the electrolyte and module, ultimately reducing costs and improving performance. For more information, visit the company’s website at www.StorEn.tech. NOTE TO INVESTORS: The latest news and updates relating to StorEn Technologies are available in the company’s newsroom at https://ibn.fm/StorEn

• Phase 1 of Southeastern project designed to pair 56,000 mining rigs with 200 megawatts of power
• ISWH already undertaking engineering, planning on the next sites to be developed in early 2022
• ISW Holdings seeks to consolidate position as a leading purveyor of digital currency and crypto-mining support services

ISW Holdings (OTC: ISWH), a global brand-management holdings company with commercial operations in renewable energy cryptocurrency, is nearing completion on the first phase of its Southeastern U.S. project (https://ibn.fm/TIL68). ISWH, which is transitioning to BlockQuarry pending a name change, has primary commercial-stage operations in cryptocurrency mining. According to ISWH, the first phase of its Southeastern project is designed to pair 56,000 mining rigs with 200 megawatts of power. The project constitutes the infrastructure build-out to deploy 20 MW of power to self-contained cryptocurrency mining Pods with environmentally conscious responsibilities. “Even with supply chain issues, we have managed to manufacture in record time,” said ISW Holdings president and chair Alonzo Pierce. “We will continue to do our best to hit our schedule objectives despite difficult market conditions, and we are thrilled to start deploying our Gen4 Pods to the site as the project ramps up. We are also excited to report that engineering and planning have gotten underway on the next sites to be developed starting in early 2022.” ISWH has partnered with Bit5ive team on the project, which is designed to take advantage of a global cryptocurrency mining hardware market that is poised to grow to an annual market value of $2.8 billion by 2024, progressing at a compounded annual growth rate of 7% between 2020 and 2024 (https://ibn.fm/Ns8RK). “Through our joint venture with Bit5ive, a global leader in cryptocurrency mining and innovative turnkey mining solutions, ISW Holdings will seek to consolidate our position as a leading purveyor of digital currency and crypto-mining support services while further expanding our global product offering within the digital data services and mining center markets,” the company stated. Sossamon Construction Co. has been involved in building the project. “We are very excited to be working with the Bit5ive team, a leading pioneer in the crypto mining space, on this exciting project,” said Larry Sossamon, president of the company. “We have made excellent progress as we near completion of the first phase of over 200 MW of crypto mining parks in South and North Carolina. These projects represent some of the most innovative of their kind, and stand to create many new jobs and new opportunities in the area.” Company management also notes that Bit5ive has delivered eight new mining Pods to the site over the past weeks with the balance to be delivered this month while simultaneously powering after installs. ISWH, soon to be BlockQuarry Corp., is quickly becoming one of the largest mining and hosting providers in the digital currency space in North America, as the company seeks to transform the financial markets of the future. ISWH’s complement of cutting-edge technologies has enhanced the Bitcoin/cryptocurrency ecosystem, enabling its customers to take advantage of real-time cost savings. At the same time, the company’s customers can feel confident that their digital transactions and assets are entirely secure because ISWH relies on a scalable blockchain infrastructure to convert unique identifiable assets (“UIAs”) into interchangeable digital assets such as Bitcoin and other fungible digital assets. For more information, visit the company’s website at www.ISWHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to ISWH are available in the company’s newsroom at http://ibn.fm/ISWH

• GreenBox POS CMO Jacqueline B. Reynolds recently appeared on The Wild West Crypto Show hosted by Crypto Cowboys Drew Taylor and Brent Bates
• Reynolds emphasized the need for businesses to adopt technologies that improve user experience, convenience, and make work easier; GreenBox offers blockchain-based, cost-saving, fast payment technology that companies can use
• Reynolds, however, noted that businesses and individuals alike are apprehensive about adopting such technology owing to distrust and a lack of education and understanding
• GreenBox is working on communications that will enhance people’s comfort level, influencing the adoption of its solutions

Guided by the goal to become the prominent, ultimate, best digital payments company globally, GreenBox POS (NASDAQ: GBOX) is leveraging its experienced, passionate workforce and differentiated, ownable, world-class technology to make people’s lives much easier as well as give them true payment solutions. This was the introductory message by company Chief Marketing Officer (“CMO”) Jacqueline B. Reynolds during an interview with hosts Drew Taylor and Brent Bates in a January 22 episode of The Wild West Crypto Show, the leading source for the latest crypto news, inside information, and exclusive interviews with the most influential personalities in the crypto space (https://ibn.fm/v92e8). Reynolds joined GreenBox last November bringing decades of experience to her CMO role, where she will shepherd all marketing strategies, including the company’s communications plan and brand positioning. Reynolds has previously led some of the world’s renowned companies, including Coca-Cola (NYSE: KO), McDonald’s (NYSE: MCD), Verizon (NYSE: VZ), Walmart (NYSE: WMT), and other Fortune 500 companies (https://ibn.fm/JJv0S). Based off of her 10-year tenure at Coca-Cola, a beverage behemoth that has become a digital-first technology company, Reynolds emphasized the need for all businesses to exploit technology to offer consumers a smooth user experience and convenience, as well as make their lives easier. “If you can think of the world’s biggest beverage company as a technology company, all of us need to be in the business of technology. When you are in the business of technology, you need to make it simple and hassle-free. User experience is what everybody is looking at,” Reynolds communicated. Notably, user experience is part of what GreenBox’s blockchain-based payment solutions are designed to provide. At the same time, the company offers technology that businesses can use to save on transaction costs. “The small business sector is what runs this country. You’re talking about a group of people that are not only entrepreneurs but also really hard working. So many people put their life savings into these small businesses in the hopes of being successful, and when you think about so much of that going to the credit card companies [in transaction charges], it’s pretty irrational. I would think that it is the most intelligent choice to try to save as many of those pennies as possible and if there’s a solution out there that gives you that raise, take full advantage of it,” Reynolds stated. However, Reynolds noted that distrust and the lack of education and understanding on available alternatives such as blockchain-based cost-saving payment and finance management solutions hinder their increased uptake. She explained that while blockchain is a new way to manage finances, there are safe, compliant, and protected ways to accomplish this, and that is what GreenBox is all about. “What we’re laser-focused on at GreenBox is ensuring that people trust what we offer; I think there’s an amount of distrust, and we know there’s a lot of fraud out there too that people need to be cautious of… For small businesses, it’s up to them to take the initiative to get educated, and it’s up to brands like us to help them in that journey. What we’re trying to do at GreenBox is truly drive the communication on this so that people have a comfort level, just the same as we’ve adopted all kinds of other things. Change is tough, but we’re here to usher people into this current world, which is very beneficial to the public,” Reynolds concluded. You can watch the full interview on YouTube at https://ibn.fm/RtK1k. GreenBox is an emerging FinTech company leveraging proprietary blockchain security to build cutting-edge, customized payment solutions for businesses. The company, which is revolutionizing cashless transactions with blockchain, offers a unified, scalable platform for businesses to accept payments, send, settle, convert, and transact. For more information, visit the company’s website at www.GreenBoxPOS.com. NOTE TO INVESTORS: The latest news and updates relating to GBOX are available in the company’s newsroom at https://ibn.fm/GBOX

• The rare earth element market expected to see interest from investors, governments around the world in coming year
• Supply will need to pick up to meet global demand for REEs, primarily from EVs
• Restoring REE production to U.S. will greatly benefit the nation’s economy and clean energy sector

Last year saw more major developments in the rare earth elements (“REE”) space than the last seven years combined, according to a recent InvesBrain report (https://ibn.fm/Mlutg). Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), which has historically been a leading U.S. uranium mining company, is keenly interested in the space, as the company has unique licenses, infrastructure and capabilities that can be deployed in the REE sector. “Following an uncertain 2020 on the back of the COVID-19 pandemic, the rare earth market continued to see interest from investors and governments around the world in 2021,” the report stated. “Rare earths, used in the high-strength magnets found in much of the latest tech, from smartphones to wind turbines to electric vehicles (“EVs”), will be a primary focus for the resource sector well into the next decade as more countries in the west work to create supply chains less dependent on China.” As a new year begins, the growth the REE sector saw in 2021 is expected to continue, according to many analysts. “There are key supply and demand dynamics to pay attention to that could impact rare earths. A key demand catalyst in 2022 will be how the chip shortage develops,” the article noted. According to Ryan Castilloux, managing director of Adamas Intelligence, a firm that provides independent research and advice on markets for critical metals and minerals, if the global chip shortage eases this year, allowing the auto industry to return to normal, he expects demand for all major rare earths to grow healthily. And if demand continues to grow at this pace, supply will need to pick up to meet the need for REEs globally. While China will almost certainly remain a key output player, Castilloux said that the next two to three years will be transitional for the supply chain outside of China in a number of ways. “We’ll see the beginnings of some major changes in 2022 outside of China and by 2025 should see a more diverse supplier landscape, albeit one still dominated by China,” Castilloux said. One of those diverse suppliers will undoubtedly be Energy Fuels, which has seen monumental progress in its efforts to enter the REE market. The company made its initial foray into the REE sector in 2019, and in September 2020, it commenced the production and shipments of an intermediate rare earth element product, called mixed rare earth carbonate, at its White Mesa Mill in Utah (https://ibn.fm/Gguw0). This is the most advanced REE material being produced in the U.S. today. Energy Fuels is set to install REE separation, and potentially REE metal-making and alloying, capabilities at the White Mesa Mill in the next few years. “This is an exciting time for all of us at Energy Fuels in both the uranium and rare earth sectors,” said Energy Fuels president and CEO Mark Chalmers. “Restoring rare earth production to the United States will greatly benefit the entire U.S. economy and manufacturing sector by providing a domestic source of clean energy materials produced to the highest global standards for environmental protection, sustainability and human rights, while also allowing for source validation and tracking from mining through final end-use applications. “With the increased demand for rare earths — up to a fivefold demand increase over the next 10 years — we will need all hands-on deck,” he continued. “Combined with the current resurgence in uranium, rare earths represent a truly an immense opportunity.” Energy Fuels is a leading US-based uranium mining company, supplying U3O8 to major nuclear utilities. Energy Fuels also produces vanadium, as market conditions warrant, as well as rare earth carbonate. With corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees in the United States, Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch ISR Project in Wyoming, and the Alta Mesa ISR Project in Texas. For more information, visit the company’s website at www.EnergyFuels.com. NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• Four cannabis bills introduced on federal level indicates import to government leaders.
• Increased compromise, bipartisanship could lead to significant changes.
• ACP is strengthening position in the sector, currently operating in two states that have passed legislation approving the substance.

Federal cannabis reform has been a roller coaster ride over the past several years, with the introduction of several bills raising hopes for legislative support, especially with a change in the White House seeming to create a more cannabis-friendly atmosphere. But 2021 didn’t bring the much-anticipated change, and many companies operating in the space, including American Cannabis Partners (“ACP”), are looking for this year to be different. “Hope soared with the possibility of federal cannabis reform in 2021,” reported a Feb. 11 “National Law Review” (“NLR”) article (https://ibn.fm/Yt1O8). “But, as 2021 continued on, optimism dwindled as any advancement in federal cannabis reform was hobbled by the inability of Congress to agree on the appropriate level of reform and the proper mechanics for passage. “Specifically, tension rose amongst the elected Democrats on whether to support incremental reform (like access to banks or removal of cannabis from the list of Schedule 1 drugs) or comprehensive legalization with provisions to address social inequities stemming from the legacy of the War on Drugs,” the article continued. “And so 2021 came to an end, and the cannabis industry saw yet another year of failed meaningful change on the federal level.” According to the NLR, however, hope isn’t lost. “If anything, last year saw more bills introduced into Congress (including two new federal legalization proposals) than ever before — clearly indicating its import to our nation’s leaders,” the article reports. “Justice Clarence Thomas from the Supreme Court even subtly advised Congress to address legalization, noting that the Federal Government’s current ‘half in, half out regime’ on cannabis strained the principles of federalism.” In a quick review of existing legislation, the NLR noted four bills — the Secure and Fair Enforcement (“SAFE”) Banking Act, the Marijuana Opportunity Reinvestment and Expungement (“MORE”) Act, the Cannabis Administrative and Opportunity (“CAO”) Act and the States Reform Act (“SRA”) — circulating around Capitol Hill that could lead to significant changes in the cannabis space. The article stated that “Congress should thus focus on forging a compromise or middle ground on these reforms to increase bipartisan support and avoid competing and inconsistent bills floating around, resulting in another year of unwanted (and unnecessary) deadlock. Indeed, the CAO could be an example of such needed compromise — especially if the drafters seriously heed the criticisms and comments provided during the bill’s review period and consider incorporating certain bipartisan elements of the SRA, like a more streamlined and lower rate tax structure.” Like other cannabis companies, American Cannabis Partners is eyeing the federal back-and-forth with more than interest; federal change could have a significant impact on the industry, which currently operates with state-level approvals but without federal support. Yet nationwide, support for cannabis is growing, with a Gallup poll showing that more than two in three Americans (68%) support legalizing the substance (https://ibn.fm/54DHn). ACP is strengthening its position in the sector, currently operating in two states — California and Michigan — that have passed legislation approving marijuana. With a total of 12 cannabis licenses, including 20,000 square feet of cultivation licenses in California and 540,000 square feet of cultivation licenses along with one retail license in Michigan, ACP is contending for first place in the U.S. cannabis industry by following proven strategies that accelerate the company’s assets, operations, expansions and market share. For more information, visit the company’s website at www.ACPFarms.com. NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://ibn.fm/ACP

• People’s ability to learn and make decisions is limited by ability to recall
• The challenge of recalling what has been read has become more difficult with the advent of the digital word
• With Pluaris, the millennia-old challenge of remembering what has been read has become infinitely easier

Five millennia ago, the human mind somewhat miraculously learned how to “connect scratches on clay tables and symbols in cave paintings with sounds of spoken language — in other words, humans learned to read” (https://ibn.fm/cGQWk). Over last 5,000 years, people have built on this basic skill, as reading is the basis of obtaining knowledge. It is this fact, combined with the recognition that people’s ability to learn and make decisions is limited by the ability to recall, that fueled Nowigence’s Inc. (NOWG) development of Pluaris(TM), an off-the shelf, cloud-based, artificial intelligence (“AI”) platform that automates reading and analysis of textual data. “The act of reading activates a symphony of brain activity, involving not only the visual and auditory systems but neural circuits that build meaning, evoke emotion, and encode memory,” states a “Forge” article. “When you read, your brain does much more than simply comprehend the words in front of you: It enables you to empathize with people you’ve never met, to engage with ideas that challenge and inspire you, to imagine other worlds. That is, if you can remember what you’re reading.” The challenge of recalling what has been read has become more difficult with the advent of the digital word. The article goes on to report that “a 2012 review paper by Ziming Liu, a professor of information science at San Jose State University who studies reading behavior, noted that when we read digital text, as opposed to words on paper, we tend to default to skimming over more careful reading. And as screens occupy an increasingly prominent presence in our lives, this kind of distracted skimming has become the new norm of reading, according to the cognitive neuroscientist Maryanne Wolf, author of ‘Proust and the Squid: The Story and Science of the Reading Brain,’ and ‘Reader, Come Home: The Reading Brain in a Digital World.’ “Based on Wolf’s own research on the neuroscience of reading, she thinks this hurried form of reading is sucking much of the benefit — and pleasure — out of one of humanity’s greatest evolutionary leaps forward,” the article continues. “It also explains why so many people struggle to remember what they’ve read even a few moments afterward, she says.” Nowigence has made this struggle infinitely less difficult with the introduction of Pluaris. The game-changing platform allows users to quickly distill knowledge. Fully customizable, Pluaris allows a user to upload websites, text and files; it even automatically monitors public news sources for identified topics of interest. The platform then gathers all the information together and — here’s where it gets good — provides summaries, extracted intelligence, and graphical analysis. Using Pluaris, readers don’t have to wade through all the information themselves, relying on their flawed human recall to remember everything. Instead, they can scan their news feed for key information, view analyzed content for unbiased importance ranking and identify what’s worth drilling down further, reducing the sheer volume of reading material and increasing resources designed to strengthen and support faulty memory. Nowigence is focused on simplifying the challenges of learning and comprehension. The company is committed to helping individuals, teams and enterprises quickly distill knowledge from massive amounts of textual data, both public and private. By integrating state-of-the-art data processing techniques in an intuitive interface at an affordable subscription price, Pluaris puts the power of data science into the hands of consumers. For more information, visit the company’s website at www.Nowigence.com. NOTE TO INVESTORS: The latest news and updates relating to Nowigence are available in the company’s newsroom at https://ibn.fm/NOW

• INND set out to enhance balance sheet and capital structure; enters shareholder-friendly financing arrangements
• Company announces cancellation of almost half of its variable convertible notes ($1.1 million), expects to eliminate remainder in several weeks
• INND remains committed to achieving financing terms that support growth and maximize value for our shareholders

InnerScope Hearing Technologies (OTC: INND), an emerging disruptive leader in the direct-to-consumer hearing technology space, announced that it has successfully renegotiated financing agreements with the holder of its securities, GS Capital Partners, LLC, canceling a series of the variable price convertible notes (https://ibn.fm/bxtG2). As a result of the restructuring transactions, the total principal amounting to $1.1 million held by GS Capital Partners has been eliminated, equivalent to almost half of the company’s outstanding variable price convertible notes. InnerScope expects to eliminate the remainder of its current variable price convertible notes in several weeks in a bid to enhance its balance sheet towards a shareholder-friendly capital structure. As an innovative disruptor in the hearing aid space, InnerScope focuses on providing affordable solutions to millions of Americans suffering from hearing loss. It is estimated that one in eight people in the United States aged 12 years or older has some form of hearing loss in both ears, which is equivalent to 30 million people across the nation. But for many of them, the hearing aids are out of reach due to prohibitive costs. Patients are usually required to shell out around $2,500 as most insurance doesn’t cover hearing aids. For high-end devices, these out-of-pocket costs can amount to over $8,000 (https://ibn.fm/xmQ79). That’s where InnerScope stepped up to the challenge, deploying innovative technology to offer consumers a range of affordable hearing health products, including Bluetooth app-controlled rechargeable hearing aids, hearing and tinnitus vitamins, various hearing aid ear cleaning products, and much more. These hearing products are available for purchase online, allowing consumers to save up to 70% of costs compared to traditional brick-and-mortar clinics. In addition, the products are available through different payment plans, including one-off payments and subscriptions through www.iHeardirect.com. Building on the progress achieved last year, when the company made key strategic moves acquiring two direct-to-consumer hearing aid competitors, iHear Medical and HearingAssist, Walmart’s largest supplier of hearing aids to position itself as a leader in the direct-to-consumer hearing aids space, InnerScope appears to remain poised for further growth. Matthew Moore, President, and CEO of InnerScope, commented upon the announcement of the debt restructuring: “InnerScope is pleased to enter into these shareholder-friendly financing arrangements, which enhances our balance sheet and capital structure. We appreciate the support from GS Capital in completing this transaction, as they continue to be a strong financial partner for us. We will work diligently to achieve the most attractive financing terms that support our growth and maximize value for our shareholders,” concluded Mr. Moore. For more information, visit the company’s website at www.INND.com and the company’s e-commerce websites www.iHeardirect.com and www.HearingAssist.com. NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

• In the first quarter of 2022, AREV acquired Wright & Well Essentials Inc., a firm with an extensive hemp and cannabis line of branded products currently sold in Oregon and expanding markets.
• The company’s online sales and marketing platform, Medicine Merchant™, is in the final stages of development; the platform has the potential to revolutionize consumer access to therapeutic interventions and personalized medicine via partnerships with telemedicine providers.
• A recent peer-reviewed study by a member of AREV’s scientific advisory board (“SAB”) has demonstrated the potential utility of specific cannabinoids against all variants of COVID-19.
• Further additions to AREV’s SAB in the second half of 2022 are expected to provide additional opportunities for establishing collaborations with academic institutions and orchestrating the acquisition of promising IP.
• AREV is developing a Ready-to-Use Therapeutic Food (“RUTF”) utilizing proprietary extraction techniques intended to treat inanition which results from the metabolic effects of starvation.
• Regulatory submission of AREV’s RESTORE™ enteral formula in the United States and Canadian markets is scheduled for the second half of 2022, with initial clinical studies expected to commence in Q4 2022.
• Verified Market Research valued the worldwide RUTF market at $363.72 million in 2019 and projected growth to $807.89 million by 2027, expanding at a CAGR of 10.5% for the forecast period.
• The global enteral feeding formulas market was valued at $5.9 billion in 2020 and is expected to expand at a CAGR of 5.9% through 2028, according to Grandview Research.

AREV Life Sciences Global (CSE: AREV) (OTC: AREVF) is a fully integrated, publicly traded, early-stage life science enterprise dedicated to delivering therapeutic interventions to public health through discovery, innovation and successful collaborations in the life science industry. The company’s leadership drives discovery programs for clinical complexities presented by malnutrition, viral infectious diseases and the inflammatory response system. AREV’s business model leverages the core competency of producing proprietary compounds through its innovative extraction methodologies, scientific advisory board (“SAB”), experienced staff, and executive leadership to drive its product pipeline. AREV’s strategy is to generate revenue from selling its branded products via its online technology platform, Medicine Merchant(TM), an enterprise marketing platform built to enable consumers to have access to novel therapeutic approaches to human nutrition, endemic diseases, and neglected chronic related co-morbidities. The company also expects to generate revenue from toll processing and government procurement of its products that address malnutrition and related health issues. AREV is focused on innovations in biomedicine and maintains a significant footprint in clinical human nutrition utilizing proprietary protein blends and terpenes, complimented with vitamins and minerals. The company has utilized its expertise to design and deliver innovation in therapeutic interventions using its exclusive botanical, fungi and marine compounds to address medical conditions driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV uses its proprietary extractions allowing characterizations from botanical and marine sources in therapeutic foods and medicines that comprise its development pipeline. Development of AREV’s pipeline is fostered by collaborations with academic centers, clinical research organizations and government institutions committed to facilitating discovery of promising new clinical approaches presented in peer reviewed journals. AREV operates under the guidance of its SAB and a growing number of strategic collaborations with CROs and academic research centers, including the Linus Pauling Institute at Oregon State University. AREV is a member of both BIOTECanada and The Biotechnology Industry Organization (“BIO”):

• BIOTECanada is the national industry association with over 200 members located nationwide, reflecting the diverse nature of Canada’s health, industrial and agricultural biotechnology sectors.
• BIO is the world’s largest advocacy association representing member companies, state biotechnology groups, academic and research institutions, and related organizations across the United States and 30+ countries.

Products AREV’s end-product and target categories include therapeutic interventions, botanical drugs, ready-to-use therapeutic food (“RUTF”), enteral nutrition formulas and early-stage small molecule antiviral therapeutics demonstrating novel mechanisms of action. Wright and Well Branded Line Wright and Well Branded Line is the company’s branded line of therapeutic cannabinoid and terpene-based formulations. The topical line includes solutions for burns, wounds, skin disorders and muscle relief, as well as a lubricant for intimacy. The oral line addresses inflammation, heart health, high blood pressure and viral infections. These products are currently produced at CBD99, a licensed processor in Sandy, Oregon. The company also has a strategic relationship with a Canadian licensed hemp and cannabis processor in Vancouver, British Columbia. SUS-TAINN(TM) The company’s products in the RUTF category are branded under SUS-TAINN(TM) (Superior Utility Supplementation Therapeutic Agent for Indicated Nutritional Needs). SUS-TAINN(TM) is the flagship line of products stemming from AREV’s collaboration with Voynich Biosciences. RUTFs like SUS-TAINN(TM) are the cornerstone to international famine response and currently represent more than 20 percent of public health commodity procurement spending. SUS-TAINN(TM) is purchased by agencies ranging from the U.S. Department of State AID for International Development to the World Food Program and is distributed by an increasingly substantial number of non-governmental organizations. RESTORE(TM) The company’s enteral nutrition product is branded as RESTORE(TM). For patients experiencing caloric compromise, enteral nutrition, a liquid form of nourishment, is often required. RESTORE(TM), the initial enteral formulation from AREV, is based on organic plant nutrition for patient populations who have demonstrated overt clinical need for rational enhanced caloric intake and micronutrient supplementation. RESTORE(TM) provides a proprietary blend of high-quality proteins, antioxidants, minerals and proven anabolic agents, combined with pre- and probiotics. The company plans to submit for Medicaid formulary inclusion and reimbursement designations in various jurisdictions characterized by the Ryan White CARE Act during the second half of 2022. REV-I1(TM) REV-I1(TM) is the company’s small molecule drug discovery model for phytomedicinalization, based on advanced computational characterization and next generation affinity selection that affords new opportunities in HIV antiretroviral research. REV inhibition offers a critical approach to inhibiting HIV replication and addressing viremia in highly conserved sanctuary regions. Phytomedicinal therapeutic discovery and development offer clinically viable approaches to a wide range of scientific challenges that currently elude successful contemporary interventions. A cornucopia of diverse validated compounds allows AREV to explore a distinguished range of promising approaches that are in stages of pre-clinical validation. Combining AREV’s versatile extraction capability with highly sensitive analytical techniques (LC-MS, MS-MS) is expected to allow new medicinal chemistry to be identified and characterized, leading to therapeutic candidates in the company’s commercial drug discovery platform. Market Overview A report from Verified Market Research valued the global plant protein market at $29.4 billion in 2020 and forecast that it could surpass $162 billion by 2030, which would make up 7.7% of the global protein market, according to a report released in August by Bloomberg Intelligence. The RUTF market was valued at $363.72 million in 2019 and is projected to reach $807.89 million by 2027, growing at a CAGR of 10.5% for the forecast period. The market is primarily driven by the efforts of governments and non-governmental organizations to reduce the rate of severe acute malnutrition. Moreover, changing trends and growing developments related to diet-related deficiencies, as well as increasing incidences of famine and disasters, are likely to fuel the growth of the RUTF market in the near future, according to the report. Management Team Michael Withrow is the founder, chairman and CEO of AREV. He is a successful natural products and technology entrepreneur with more than 25 years of experience. He has started and sold companies and has worked with companies such as CAVA Health Care (formerly Alternative Extracts Inc.), North American BioExtracts Inc., and Canadian Pacific Phytoplankton Ltd. He has also served as president and CEO of a specialty cannabis technology company. Kevin Phelps, CPA, is a director at AREV. He is CEO and president of Immune Therapeutics Inc., a bio-pharmaceutical company. He began his career with Price Waterhouse before joining Eastman Kodak Company as part of an executive team that successfully spun out the Bio Products Division into Genencor International Inc., an international industrial bio-chemicals company. He later joined Trillium Group, a regional private equity firm, as a partner, where he served on behalf of the firm as CFO of Vaccinex Inc., a vaccine development company, and chairman of AccuMed Inc., a medical device company. He has served as Chairman of Oyagen, a biotech that over the past decade has developed drug discovery methods that have enabled it to explore vulnerabilities in HIV, Ebola and coronaviruses. Denby Greenslade is corporate secretary and interim CFO at AREV. She has served as corporate secretary and director for several companies in the mining, biotech and IT industries and has more than 15 years of corporate secretarial, corporate governance, and securities regulation experience. She graduated from Simon Fraser University with a Bachelor of Arts in Communication. Allan Echino is a director at AREV. He was a founder and director of Corlac Resources, an oil producer, and Calroc Industries, an oil service company based in Alberta. Mr. Echino arranged funding for a licensed producer in the cannabis sector and quickly learned the business and health benefits of cannabis and mushrooms. Mel Maxwell is a director at AREV. During his 40-plus year career, he has founded six companies. His degrees in business and computer science initially took his career toward IT ventures that entailed software development, IT consulting, e-commerce solutions, real estate development, pathogen remediation solutions and wholesale vehicle aggregation. He finds continued enjoyment in consulting with other businesses and entrepreneurs. Scientific Advisory Board Roscoe M. Moore, Jr., DVM, MPH, PhD, a former United States Assistant Surgeon General, provides strategic planning for AREV’s nutritional and drug discovery platforms as chairman of the company’s scientific advisory board. Dr. Moore is a member of the board of advisers of the Institute of Human Virology (“IHV”) and the board of directors of the Global Virus Network associated with IHV, University of Maryland Medical Center. IHV is the first research institute in the U.S. to link basic science, population studies, and clinical trials in an effort to develop new vaccines and treatments; its 80 faculty members contribute to research on pandemic pathogens, ranging from COVID-19 to HIV. Dr. Moore served with the United States Department of Health and Human Services (“HHS”) and was responsible, for the last 12 years of his career, for global development support within the Office of the Secretary, HHS, with primary emphasis on implementing innovations in essential health care commodity procurement programs for resource-challenged countries. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service, entering with the U.S. National Institutes of Health (“NIH”) and rising to the rank of Rear Admiral. Dr. Moore worked at the Center for Veterinary Medicine, U.S. Food and Drug Administration (“FDA”), before becoming senior epidemiologist within the National Institute for Occupational Safety and Health of the U.S. Centers for Disease Control and Prevention (“CDC”), where he also served as an epidemic intelligence service officer. Robert Melamede, PhD, received his doctorate in molecular genetics and biochemistry from the University of the City of New York Graduate Center, focusing on base excision repair of free radical damages in DNA. For decades, he led laboratory efforts in a world-class, federally funded lab, where he discovered endonuclease VIII. Dr. Melamede did a sabbatical at the Scripps Institute and subsequently established an in vitro monoclonal antibody facility at the University of Vermont, developing antibodies to free radical damages in DNA and to DNA repair enzymes. Working with a collaborator, Dr. Melamede worked on metabolism and cancer cells as a professor and chair of the biology department at the University of Colorado at Colorado Springs. He co-founded Cannabis Science Inc., a public company, retiring as the company’s chief executive in 2014. Dr. Melamede continues his innovative research in the private sector. Harold Smith, PhD, is the founder, CEO, and president of Oyagen Inc., a biotechnology company developing therapeutics for various disease states, including HIV and cancer. Dr. Smith is also a tenured professor of biochemistry and biophysics at the University of Rochester, School of Dentistry and Medicine, with additional appointments as a professor in genetics and pathology and as a member of the Center for RNA Biology. Richard Van Breemen, PhD, is a Professor of Medicinal Chemistry in the Department of Pharmaceutical Sciences of the College of Pharmacy at Oregon State University. His research interests include cancer prevention by dietary antioxidants and prostate cancer prevention by the carotenoid lycopene, mass spectrometry-based pharmacological screening of natural products and combinatorial libraries for drug discovery, and high throughput screening to assess drug metabolism, toxicity and bioavailability. Dr. Van Breemen made The Analytical Scientist’s Power List in 2020 and 2021. His work in biomedical mass spectrometry earned him an initial spot, and he clocked in the Top 100 analytical scientists from around the world on the Power List in 2021. Dr. Blake Hawley is the founder & CEO of Motega Health Inc. Dr. Hawley has worked in animal health, pharma and food across 23 countries and four continents. He holds an MBA from KU and his doctorate in veterinary medicine and zoology degrees from NC State. He serves on multiple non-profit advisory boards, including the KU MBA Advisory Board. Dr. Hawley is a 2017 graduate of Pipeline Entrepreneurs and a graduate of the Village Capital Agricultural 2016 Entrepreneur Cohort. Dr. Hawley previously served as the General Manager of Australasia; Regional General Manager of Russia and Central Eastern Europe (consisting of 22 countries); and Managing Director of the United Kingdom and Ireland for Hill’s Pet Nutrition, a division of Colgate-Palmolive. His experience includes 10 years of profit and loss responsibilities in these territories, with consistent double-digit annual revenue growth in each of the 10 years. He oversaw products competing in the arthritis, dermatology, obesity, gastrointestinal, urinary, and cancer markets, among others. Dr. Hawley also has background in e-commerce, data analytics, and social media and most recently served as Worldwide Director of Global Digital for Hill’s Pet Nutrition. Uma Dhanabalan, MD, MPH, FAAFP, MRO, CMS, advises AREV on product development and formulation. She is the founder and CEO of Global Health & Hygiene Solutions LLC, whose mission is to promote wellness and prevent illness locally and globally and runs an independent practice at Uplifting Health & Wellness in Cambridge, Massachusetts. Dr. Dhanabalan, a fellow of the American Academy of Family Physicians, graduated from UMDNJ, Newark, New Jersey, with her medical degree and trained in family medicine at MUSC in Charleston, South Carolina; she earned her master’s degree in public health from Harvard’s School of Public Health in Boston, Massachusetts, and continued her training at Harvard in occupational and environmental medicine. Special IP Advisor Douglas Sorroco practices in all areas of intellectual property law including patent, trademark, copyright, technology, and e-commerce and assists clients with intellectual property matters requiring litigation, licensing, technology counselling and complex transactions. Mr. Sorroco is ranked in Band 1 (the top band) for intellectual property law by the highly regarded Chambers USA: America’s Leading Lawyers for Business 2021, and he was selected for inclusion in The Best Lawyers in America(R) 2022 for Litigation – Intellectual Property, Litigation – Patent, Patent Law and Technology Law. In 2021, Best Lawyers named him the Oklahoma Lawyer of the Year for Technology Law. In 2021, Managing Intellectual Property continued to rank Doug as an IP Star. Mr. Sorroco was selected for inclusion in Oklahoma Super Lawyers 2021 and was also selected by attorney peers for inclusion in Oklahoma Super Lawyers – Rising Stars Edition (2010). For more information, visit the company’s website at www.ArevLifeSciences.com. NOTE TO INVESTORS: The latest news and updates relating to AREVF are available in the company’s newsroom at https://ibn.fm/AREVF